

Palonosetron

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
Palonosetron injection

APPROVAL CRITERIA

Requests for palonosetron for injection may be approved for adults as prevention of any of the following:

- I. Acute or delayed nausea and vomiting associated with initial and repeat courses of moderately or highly emetogenic cancer chemotherapy; **OR**
- II. Postoperative nausea and vomiting (PONV) for up to 24 hours following surgery.

Requests for palonosetron for injection for pediatric individuals aged 1 month to less than 17 years may be approved if the following criterion are met:

- I. Individual is using for prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy.

Palonosetron for injection may not be approved when the above criteria are not met and for all other indications.

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2019. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: September 27, 2019.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.
5. NCCN Clinical Practice Guidelines in Oncology™. © 2019 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on September 27, 2019.
 - a. Antiemesis. V1.2019. Revised February 28, 2019.